NeurAxis (NYSEAM:NRXS) FY Conference Summary Company Overview - **Company Name**: NeurAxis - **Ticker**: NRXS - **Industry**: Med Tech, specifically focused on neuromodulation therapies for gastrointestinal (GI) disorders - **Market Position**: Growth stage company with over 10 years of experience, recently expanded from pediatric to adult indications [2][3] Key Points and Arguments Corporate Developments - NeurAxis has secured a **Category I CPT code** for its PENFS technology effective January 1, 2026, which is crucial for scaling the technology and obtaining insurance coverage [3][4][21] - The company has expanded its **commercial payer coverage** to over **100 million covered lives**, enhancing access to its treatments [4][24] - In 2025, NeurAxis reported revenues exceeding **$3 million** with a gross margin of approximately **84%** [4][20] Market Opportunity - The **serviceable available market** for NeurAxis is estimated at **$22 billion** in the U.S., with specific indications like functional abdominal pain and IBS representing a **$3 billion market opportunity** [8][9] - There are about **6 million patients** in the U.S. with functional abdominal pain and IBS, with **10%** classified as debilitated [9] Clinical Focus - NeurAxis is concentrating on **functional abdominal pain** and **functional dyspepsia** in both pediatric and adult populations, with ongoing clinical trials for multiple indications [5][6] - The company emphasizes the importance of strong clinical data to support insurance coverage and reimbursement, which is critical for revenue growth [6][10] Competitive Advantage - NeurAxis is the only FDA-approved treatment recommended in pediatric guidelines for gut-brain interaction disorders, providing a unique market position [7][10] - The company has conducted **16 publications** of investigator-initiated research, demonstrating the efficacy and safety of its technology [12] Financial Outlook - NeurAxis has a clear path to profitability, with expectations for gross margins to approach **90%** in the coming year [29] - The company had **$5 million** in cash at the end of the previous quarter, with a monthly burn rate of approximately **$450,000-$500,000** [29][30] Challenges and Strategies - The company faces challenges in scaling due to previous lack of insurance coverage and the need for more trained providers to utilize the technology [17][22] - NeurAxis is actively working to increase insurance policy coverage and improve its market presence through strategic partnerships and data presentation [26][27] Additional Important Information - The management team is experienced, with 90% of the team having been involved in the company's growth [8] - The company is focused on maintaining a strong intellectual property portfolio, which is expected to last until **2039** [18] - NeurAxis is committed to transitioning its technology to frontline treatment options for patients, aiming for earlier intervention and better long-term outcomes [27][28]

LivaNova FY Conference Summary Company Overview - **Company**: LivaNova (NasdaqGS:LIVN) - **Industry**: Medical Technology (MedTech) - **Recent Revenue**: Approximately $1.3 billion in the last 12 months as of September 2025 [3] - **Core Businesses**: - Cardiopulmonary: Heart-lung machines, oxygenators, and technologies for open heart surgery, with over 70% market share in open heart procedures globally [3] - Epilepsy: Neuromodulation therapy for drug-resistant epilepsy, transforming the lives of over 175,000 patients [4] Key Points and Arguments Financial Performance - **Growth Metrics**: - 10% organic revenue growth - 17% EPS growth - Over $400 million in adjusted free cash flow [4] - **Strategic Evolution**: Significant portfolio reshaping from 2019 to 2022, divesting low-growth assets to focus on promising early-stage opportunities [5] Market Opportunities - **Epilepsy Market**: - Valued at $700 million, significantly underpenetrated with fewer than 10% of eligible patients receiving non-pharmacotherapy annually [8] - **Cardiopulmonary Market**: - Over $2 billion market, experiencing mid-single-digit growth due to aging population and increased surgical complexity [9] - **Obstructive Sleep Apnea (OSA)**: - Rapidly growing market expected to reach $1 billion, with double-digit growth driven by increased awareness and diagnosis rates [9] - **Difficult-to-Treat Depression (DTD)**: - Potential billion-dollar market opportunity pending CMS reimbursement decision [10] Strategic Focus - **Core Business Strength**: Leadership in epilepsy and cardiopulmonary markets provides a foundation for durable growth and cash generation [7] - **Neuromodulation Expertise**: Leveraging capabilities from epilepsy to enter OSA and DTD markets [10] - **Innovation and Clinical Evidence**: Focus on impactful clinical studies and product innovations to drive market penetration [13] Financial Projections - **Revenue Growth**: - Mid- to high single-digit revenue growth expected in cardiopulmonary business [17] - Mid-single-digit CAGR projected for epilepsy [17] - OSA revenue expected to scale between $200 million and $400 million by 2030 [18] - **Operating Margins**: - Anticipated adjusted operating income margin expansion by over 300 basis points in cardiopulmonary and 200 basis points in epilepsy [17] Reimbursement and Market Access - **Improved Reimbursement**: - Close to 50% increase in reimbursement for VNS Therapy procedures under Medicare, enhancing economic viability for providers [35] - **CORE-VNS Study**: Positive real-world evidence supporting the efficacy of VNS Therapy, expected to change market perceptions and drive penetration [39] Capital Allocation Strategy - **Priorities**: - Continued investment in core epilepsy and cardiopulmonary businesses - Focus on OSA commercialization and infrastructure development - Tuck-in M&A opportunities as a growth tool [32][33] CMS Engagement for DTD - **Current Status**: Collaborative discussions with CMS regarding reimbursement for DTD, with a formal request for reconsideration expected soon [41][42] Additional Important Insights - **Market Penetration Strategies**: Plans to expand penetration in existing accounts and re-engage accounts that exited VNS practice due to unfavorable economics [37] - **PolySync Technology**: New titration algorithm showing promising results, with 8 out of 10 non-responders converting to responders, indicating potential for improved patient outcomes [27] This summary encapsulates the key insights from LivaNova's FY Conference, highlighting the company's strategic direction, market opportunities, financial performance, and future growth potential.

Core Insights - NeurAxis, Inc. has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract effective December 1, 2025, establishing it as a federal contractor and providing a pathway into the VA health system, which serves nearly 7 million active patients annually [1][3] - The company's proprietary technology, IB-Stim, is an FDA-cleared percutaneous electrical nerve field stimulator for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in functional dyspepsia [2][4] - The VA contract is expected to support sustained commercial momentum for NeurAxis entering 2026, alongside broadening reimbursement and increasing clinical adoption [1][3] Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies for chronic and debilitating conditions in both children and adults, with a commitment to advancing science and evidence-based medicine [4] - IB-Stim is the only FDA-cleared therapy for functional dyspepsia, highlighting its unique position in the market [2] - The company is planning to dedicate sales resources to the VA and scale efforts as utilization of IB-Stim grows, supported by a Category I CPT code effective January 1, 2026 [3]

Summary of Nyxoah (NYXH) 2025 Conference Call Company Overview - **Company Name**: Nyxoah - **Industry**: Medical Technology (MedTech) - **Focus**: Innovative solutions for treating obstructive sleep apnea (OSA) patients - **Key Product**: Genio solution, which received FDA approval on August 8, 2025, and launched in the U.S. on August 11, 2025 [6][20] Market Insights - **Obstructive Sleep Apnea Market**: - Significant market with millions of patients in the U.S. suffering from moderate to severe OSA [5][7] - The market is described as having "blockbuster potential" due to the large number of eligible patients for treatment [9] - **Current Treatment Landscape**: - CPAP (Continuous Positive Airway Pressure) is the gold standard but has a compliance issue, with nearly 50% of patients discontinuing use after 2-3 years [10][11] - Genio aims to fill the gap for patients who cannot tolerate CPAP [19] Product Differentiation - **Genio Device Mechanism**: - Utilizes bilateral stimulation to maintain airway openness during sleep by contracting the genioglossus muscle [12][14] - No implantable battery, making it more patient-friendly and MRI compatible [14][15] - Software updates can be performed without surgery, enhancing user experience [15] Commercial Strategy - **U.S. Market Entry**: - Focused launch strategy targeting high-volume centers and establishing relationships with key customers [20][26] - Initial revenue expected to ramp up in 2026, with foundational work being done in 2025 [27][28] - **Operational Expenditures**: - R&D spending expected to increase in the mid-single digits percentage-wise compared to the previous year [30] - SG&A expenses projected to rise by 66-75% due to investments in the U.S. commercial organization [31] Financial Outlook - **Current Cash Position**: - €43 million in cash as of June, with a reduced cash burn from €23 million to €20 million in Q2 [38][39] - Sufficient cash to sustain operations into 2026, with plans to evaluate capital-raising options [40] - **Revenue Breakeven Point**: - Estimated to be around $200 million, which is lower than competitors, allowing for a more targeted commercialization approach [41] Future Developments - **Data Collection and Registry**: - Plans to establish a registry to collect patient data and health economic data to support payer negotiations [32][34] - **Future Product Iterations**: - Development of a smart implant capable of automatic adjustments and a closed-loop system for enhanced patient experience [35][36] Key Takeaways - Nyxoah is positioned to capitalize on a significant market opportunity in the OSA space with its innovative Genio solution - The company is focused on building a strong commercial presence in the U.S. while managing operational expenditures effectively - Future growth will depend on successful market penetration, patient compliance, and ongoing product development initiatives [6][20][27]

CVRx (CVRX) FY Conference Summary Company Overview - **Company**: CVRx - **Industry**: Medical Devices, specifically focusing on neuromodulation therapy for cardiovascular diseases - **Annual Total Addressable Market (TAM)**: $2.2 billion with a well-defined patient population and limited competition [2][6] Key Points and Arguments Heart Failure Market - Heart failure is a significant health issue in the U.S., leading to approximately 1 million hospital discharges, 1.3 million emergency room visits, and $70 billion in annual spending by the end of the decade [3] - Current treatment options include guideline-directed medical therapy (quad therapy), but only 1% of patients reach the maximum tolerated dose, and 40% discontinue at least one medication within the first year [4] - The existing therapies have minimal impact on quality of life, with patients expressing a desire for symptom improvement over longevity [5][6] Barostim Therapy - Barostim therapy targets the "walking wounded" heart failure patients who are symptomatic despite optimal medical therapy [6] - The Heart Failure Society of America has acknowledged the need for device therapy after three to six months of optimal medical therapy [6] - Clinical data from the BEAT HF trial shows Barostim therapy provides significant improvements in quality of life, exercise capacity, and a 68% improvement in NYHA functional class [10] - A real-world study indicated an 85% reduction in hospitalizations post-implantation of Barostim [11] Go-to-Market Strategy - The company is focusing on optimizing its sales strategy, which includes building a world-class sales organization and addressing barriers to therapy adoption [12] - 41% of the sales force has been newly hired in the past year, which has caused some disruption but is expected to stabilize [13][18] - Recent reimbursement developments include achieving a permanent inpatient payment of $43,000 for the procedure, which aligns inpatient and outpatient payments [14][15] Financial Performance and Guidance - Q2 showed a 15% year-over-year growth in heart failure revenue, with guidance narrowed to $55-$57 million for the year [17][23] - The company has $95 million in cash, sufficient for at least three years of operations, with no immediate need for additional capital [42][43] - Gross margins are currently around 84%, with potential for improvement as production capacity increases [45][46] Clinical Trials and FDA Interaction - Ongoing discussions with the FDA regarding trial design for indication expansion, with an expected timeline of 5-7 years for trial completion [38][40] - The estimated cost of the trial is between $20-$25 million, which is manageable within the current financial framework [43] Additional Important Insights - The company is adapting its market segmentation strategy to include tier three and four accounts, recognizing potential in previously overlooked centers [26][28] - Advocacy efforts for a level six reimbursement code are ongoing, with a potential increase in reimbursement rates anticipated [33][34] - The company is focused on executing its plans and expects to see benefits from recent changes as it moves into the next fiscal year [47]

Financial Data and Key Metrics Changes - LivaNova reported a 10% organic revenue growth compared to the previous year, driven by strong performance in the cardiopulmonary and neuromodulation segments [5][28] - Revenue for the quarter was $353 million, reflecting a 9% increase on a constant currency basis and a 10% increase on an organic basis [28] - Adjusted gross margin increased to 69% from 68% in the previous year, attributed to positive pricing and geographic mix [29] - Adjusted diluted earnings per share rose to $1.05 from $0.93 in the prior year [34] Segment Performance Changes - Cardiopulmonary segment revenue was $199 million, a 13% increase year-over-year, with heart-lung machine revenue growing in the low double digits [11][12] - Epilepsy segment revenue increased by 6% year-over-year, with U.S. revenue growing by 5% and Europe and rest of the world combined growing by 9% [13][14] - The company expects epilepsy revenue growth for the full year to be between 4.5% and 5.5%, up from previous guidance of 4% to 5% [16] Market Data and Key Metrics Changes - The cardiopulmonary segment anticipates a revenue growth of 12% to 13% for the full year, revised from 9% to 10% [12] - The company is preparing to launch the Essence product in China, which is expected to be a significant market for heart-lung machines [12][72] Company Strategy and Industry Competition - LivaNova is focused on expanding its portfolio into high-growth markets and addressing large patient populations with significant unmet needs, particularly in obstructive sleep apnea and difficult-to-treat depression [41] - The company is making progress towards CMS reimbursement reconsideration for VNS therapy in treatment-resistant depression, which could enhance market access [41][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining strong organic growth due to robust demand and disciplined execution across the portfolio [5] - The company is optimistic about the impact of the proposed CMS reimbursement changes for end-of-service procedures, which could significantly improve hospital economics [52][51] Other Important Information - The company has initiated a process with CMS to seek national Medicare coverage for VNS therapy in unipolar patients with treatment-resistant depression [21] - LivaNova's cash balance increased to $594 million, up from $429 million at the end of 2024, primarily due to the reclassification of restricted cash [34] Q&A Session Summary Question: Can you elaborate on the positive data from the epilepsy business and its implications for growth? - Management highlighted the large study demonstrating significant seizure reduction, which is expected to enhance patient access and drive growth [45][46] Question: What is the expected impact of the CMS proposal to boost end-of-service procedures to level five? - Management noted that this change could lead to a 48% increase in reimbursement, positively impacting procedure penetration and provider sustainability [51][52] Question: Can you break down the oxygenator business and underlying demand? - Management indicated healthy procedure growth and market share gains, with supply not yet catching up to demand [56][58] Question: How does the company view the commercialization of the obstructive sleep apnea program? - Management expressed confidence in internal commercialization capabilities while remaining open to potential partnerships [96][97]

Financial Data and Key Metrics Changes - LivaNova reported a 10% organic revenue growth compared to the previous year, driven by strong performance in the cardiopulmonary and neuromodulation segments [5][29] - Revenue for the quarter was $353 million, reflecting a 9% increase on a constant currency basis and a 10% increase on an organic basis [29] - Adjusted gross margin increased to 69% from 68% in the previous year, attributed to positive pricing and geographic mix [30] - Adjusted diluted earnings per share rose to $1.05 from $0.93 in the prior year [34] - Cash balance increased to $594 million from $429 million at year-end 2024, while total debt decreased to $431 million from $628 million [34][35] Segment Performance Changes - Cardiopulmonary segment revenue was $199 million, a 13% increase year-over-year, with heart-lung machine revenue growing in the low double digits [11][12] - Epilepsy segment revenue increased by 6%, with U.S. revenue growing by 5% and Europe and rest of the world combined growing by 9% [13][14] - The company expects cardiopulmonary revenue to grow 12-13% for the full year 2025, up from a previous forecast of 9-10% [12] - Epilepsy revenue growth forecast for 2025 was raised to 4.5-5.5% from 4-5% previously [16] Market Data and Key Metrics Changes - The company anticipates launching the Essence heart-lung machine in China in Q3 2025, which is expected to be a significant market for the product [12][72] - The CMS proposal to increase reimbursement for end-of-service procedures to level five could significantly impact procedure penetration, as it affects 70% of implants in the U.S. [52][53] Company Strategy and Industry Competition - LivaNova is focused on expanding its portfolio into high-growth markets, particularly in obstructive sleep apnea (OSA) and difficult-to-treat depression (DTD) [42] - The company is investing in its core businesses to sustain market leadership and clinical excellence, with a strong emphasis on innovation and regulatory achievements [42][27] - The company is optimistic about the competitive landscape, noting that it has gained market share in the cardiopulmonary segment [59] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth and capitalize on opportunities in the epilepsy and cardiopulmonary segments [42] - The management highlighted the importance of recent clinical data in driving awareness and adoption of VNS therapy for drug-resistant epilepsy [20][49] - The company remains focused on addressing significant unmet needs in the market, particularly in OSA and DTD [42] Other Important Information - The company is working closely with CMS to seek national Medicare coverage for VNS therapy in treatment-resistant depression [22][24] - The company is also making significant investments in IT infrastructure and innovation to drive long-term efficiencies and scalability [32][39] Q&A Session Summary Question: Can you elaborate on the positive data from the epilepsy business and its implications for growth? - Management highlighted the large study demonstrating significant seizure reduction, which is expected to enhance patient access and drive growth [46][49] Question: What is the expected impact of the CMS proposal to boost end-of-service procedures to level five? - Management noted that this proposal could significantly improve reimbursement for providers, potentially increasing procedure penetration [52][53] Question: Can you break down the oxygenator business and its demand versus capacity? - Management indicated healthy procedure growth and market share gains, but noted that supply is not yet catching up with demand [59][60] Question: What are the expectations for the launch in China? - Management expressed confidence in the Essence product's launch in China, indicating it is a significant market for the company [72] Question: What are the plans for the obstructive sleep apnea program? - Management is confident in its ability to commercialize the OSA portfolio internally but remains open to partnerships if beneficial [96]